Alveavax-v1.2
/ Alvea Holdings
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 06, 2023
Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
(clinicaltrials.gov)
- P1 | N=130 | Completed | Sponsor: Alvea Holdings, LLC
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1